Insider · CIK 0001644489
David-Alexandre C Gros
Files at ELDN (Eledon Pharmaceuticals, Inc.). First filing -, latest -.
In brief
David-Alexandre C Gros files SEC Form 4 as CEO and director at ELDN (Eledon Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David-Alexandre C Gros has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | ELDN Eledon Pharmaceuticals, Inc. | AGrant or award Common Stock | +354,454 | $0.00 | $0 | 363,454 | Aug 4, 2026 |
| Jul 31, 2026 | ELDN Eledon Pharmaceuticals, Inc. | FTax withholding Common Stock | -194,791 | $3.38 | $658k | 168,663 | Aug 4, 2026 |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jan 13, 2025 |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +66,500 | $0.00 | $0 | 66,500 | Jan 13, 2025 |
| Nov 21, 2024 | ELDN Eledon Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,015,743 | $0.00 | $0 | 1,015,743 | Nov 22, 2024 |
Questions about David-Alexandre C Gros
Answered from the filings on this page, as of the latest one.
Is David-Alexandre C Gros buying or selling?
David-Alexandre C Gros has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David-Alexandre C Gros's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David-Alexandre C Gros has 0.
Where does David-Alexandre C Gros file Form 4?
David-Alexandre C Gros has filed Form 4 at ELDN (Eledon Pharmaceuticals, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.